Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
09. Dezember 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, December 9, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene AG reports Financial Results and Business Update for Q3 2024
24. Oktober 2024 01:30 ET
|
Medigene AG
Planegg/Martinsried, October 24, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene will Present at ASGCT 2024 and Host R&D Event
02. Oktober 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, October 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
14. September 2024 07:30 ET
|
Medigene AG
Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...